A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant
Latest Information Update: 13 Apr 2026
At a glance
- Drugs Ciclosporin (Primary)
- Indications Bronchiolitis obliterans
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BOSTON-3
- Sponsors Breath Therapeutics; Zambon SpA
Most Recent Events
- 07 Apr 2026 Status changed from active, no longer recruiting to discontinued. ( Study was terminated for business reasons. The earlier study end is not related to any safety concerns or data issues identified at any site or within the overall study data collected to date.)
- 27 Jan 2025 Planned End Date changed from 1 Sep 2024 to 1 Dec 2025.
- 27 Jan 2025 Planned primary completion date changed from 1 Sep 2024 to 1 Dec 2025.